September

Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

ByThis article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned,funded by Eisai Inc.

September

Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting

Crizotinib Active in ALK-Positive Pediatric Cancer

Oncology Leaders Praise Health Law Ruling-With Caveats

How Can We Get Better Value in End-of-Life Care?

Down the Road for Breast Cancer

How Payers and Oncologists Really Feel About Oncology Pathways

Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience

Oncology Patient-Centered Medical Home

Medical Drug Benefit Management in the Pathway Era

Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers

Implementation of Cancer Clinical Care Pathways

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

The Keys to Obtaining Best Value in Non-Small Cell Lung Cancer

Achieving Quality and Containing Cost Through Oncology Pharmacy Management

Treatment and Cost Implications of Pertuzumab

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

Trending on AJMC

FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss

FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy

Top 5 Most-Read Pulmonary Fibrosis Content of 2025

ICYMI: Highlights From ASCO 2025

AI Ultrasound Models Show High Accuracy in Ovarian Cancer Diagnosis